"Et tu, Brute?" -A Case of Ixazomib-Induced Cancer Therapy-Related Cardiac Dysfunction
Abstract
An 81-year-old man with a history of multiple myeloma presented with decompensated heart failure (HF). Although his baseline left ventricular ejection fraction (LVEF) was preserved, it significantly declined to 35% at 13 months after the initiation of ixazomib. Considering the chronological relationship between the timing of ixazomib treatment and symptom onset, prior normal echocardiography, and multimodal imaging findings, ixazomib-induced cancer therapy-related cardiac dysfunction (CTRCD) was strongly suspected. Despite the discontinuation of ixazomib and continued administration of guideline-directed medical therapy, his LVEF has not recovered to date. We herein report a rare case of ixazomib-induced irreversible CTRCD.
Fields of Study & Subjects
Multiple Myeloma Research and Treatments
Lung Cancer Treatments and Mutations
Chemotherapy-induced cardiotoxicity and mitigation
Publication details
- Journal / source
- Internal Medicine
- Publisher
- Japanese Society of Internal Medicine
- Volume
- 65
- Issue
- 19
- Pages
- 2586-2591
- Publication date
- 1 January 2026
- Language
- EN